Titan Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Titan Pharmaceuticals
Industry Pharmaceuticals
Headquarters California
Key people
Sunil Bhonsle
Number of employees
13 (June 2015)
Website www.titanpharm.com

Titan Pharmaceuticals, Inc. is a California biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.[citation needed]

Titan's principal asset[citation needed] is Probuphine,[1] a slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”)[2] for the treatment of opioid addiction or chronic pain. Template:As of 2015, it was in phase 3 trials.[3]


  1. ^ Probuphine®
  2. ^ Solof, Barry (2013). The therapist's guide to addiction medicine a handbook for addiction counselors and therapists. New York: Central Recovery Press, LLC. p. 98. ISBN 9781937612443. Retrieved 21 September 2015. 
  3. ^ "Probuphine® Program Update". Titan Pharmaceuticals. Retrieved 21 September 2015. 

External links[edit]